TP53 and neoplasm: The observed mutation profiles further distinguish high- and low-LRPG scores in PCa, with patients with higher scores showing increased mutation frequencies in oncogenic pathways such as the RTK-RAS, WNT, and Hippo and a higher prevalence of TP53 mutations, known to disrupt cell cycle control and tumor suppression [53–57].